Peter Llewellyn-Davies, President of BIOTECH AUSTRIA, is delighted: “The continued high turnout and very positive feedback underscore the summit’s role in reinforcing Austria’s position as a leading life sciences location and promoting cross-border collaboration. I would also like to sincerely thank all attendees, sponsors, and especially our co-hosts who helped make this event truly unforgettable.”
Keynotes set a practical, forward-looking tone: Harpreet Singh, CEO and Co-Founder of Immatics, recounted the company’s trajectory and emphasized that progress isn’t always a straight line, but requires resilience and flexibility. Caroline Schober (RCPE GmbH), speaking in line with BIOTECH AUSTRIA’s 2025 motto “Artificial vs. Agile Intelligence” explored the crucial role of the human factor for biotech innovation in an era increasingly shaped by AI. Patrick Frei, Founder & CEO of Venture Valuation, presented a deep dive into valuing biotech companies for financing and partnering and closed with a fireside chat going into a detailed analysis of his experience. The program also featured high-level panels on scientific challenges and opportunities or the latest trends in financing and venture capital, plus talks covering topics such as BIOTECH AUSTRIA’s Austrian life science strategy initiatives and its task forces, as well as company presentations and start-up pitches.
Lejla Pock, CEO of Human.technology Styria and local co-host of the summit, added: “Hosting this year’s Biotech Summit here in Graz again was a privilege. Innovation thrives where people meet, share ideas, and build trust, and that spirit of collaboration was visible throughout the event. Graz, with its scientific excellence and entrepreneurial spirit, provided the perfect backdrop for that exchange.”
Social and networking events supported deal-making and relationship building, from a preconference Hike & Dine through the Styrian vineyards to the dinner at the Schlossberg restaurant and dancing well into the morning hours. With several hundred meetings booked, the 1:1 partnering sessions allowed industry representatives from across the biotech value chain to build partnerships and explore new business opportunities.
Klaus Weinberger, CEO at Health Hub Tirol, concluded: “With such a strong participation and lively discussions, this year’s summit demonstrated the momentum and collaborative spirit of Austria’s biotech scene. We look forward to carrying this energy forward when the Summit returns to Innsbruck on October 13-14, 2026. "
For further information and to revisit highlights of the 3rd BIOTECH SUMMIT AUSTRIA, please visit the BIOTECH SUMMIT AUSTRIA website.
About Biotech Austria
Since December 2020, BIOTECH AUSTRIA has been the voice of the Austrian biotech industry, enabling and connecting a non-governmental ecosystem so that businesses can start, grow and deliver world-changing innovation. Life Sciences are a key industry in Austria, and biotechnology is one of the fastest-developing sectors with high growth dynamics and international competitiveness. BIOTECH AUSTRIA is constantly expanding its network with new members and supporters in order to gather even more expertise under one roof. BIOTECH AUSTRIA represents over 100 biotech and life science companies, from start-ups to big pharma, academic institutions, research institutes, organisations and service providers to the sector. More information can be found at www.biotechaustria.org or on LinkedIn.
About Human.technology Styria
Human.technology Styria GmbH (HTS) is a cluster organization founded in 2004 with a focus on Life Sciences. It operates in three strategic priority areas: Medical Technology, Pharmaceuticals & Biotechnology, and Health & Sustainability. Additionally, HTS is actively involved in cross-cutting topics such as Start-Ups, Digitalization, and Qualification. The cluster sees itself as a bridge-builder between research, development, and industry, aiming to create synergies, enable innovations, forge new partnerships, and enhance the national and international visibility of the region. Companies within the cluster community benefit from exclusive service offerings related to Contact Management, Business Development, Internationalization, Networking, Events, Communication, and Knowledge Transfer. Within the environment of the Styrian Life Science Cluster, there are 150 companies with 40,000 employees generating a turnover of 5 billion euros. Approximately one-third of this can be attributed to the Pharma/Biotech sector. More information can be found at www.humantechnology.at.
About Health Hub Tirol
Tirol is a strong life sciences location. Successful companies and outstanding universities ensure a high research output, over 11,000 jobs and an industry turnover of almost 3 billion euros per year. Almost 100 innovative companies, institutions and universities are networked in the Cluster Life Sciences Tirol, which is based at the Standortagentur Tirol. In addition, the state of Tirol invests in a location development program for life sciences via Lebensraum Tirol Holding, which is implemented by Standortagentur Tirol and its subsidiaries. This program aims to drive innovation in the fields of medical technology, digital health, pharmaceuticals and biotechnology. Tirol is to be positioned as a top European life sciences region by 2030. One pillar of the program is the Health Hub Tirol, which works closely with the Cluster Life Sciences Tirol and Startup.Tirol to provide (lab) space and a wide range of startup services. More information can be found at www.standort-tirol.at and www.healthhub.tirol.
For post-event inquiries and additional information, please contact:
BIOTECH AUSTRIA
Christine Llewellyn-Davies
Head of Operations
+43 670 6030601
E-mail: info(at)biotechaustria.org
Health Hub Tirol
Klaus Weinberger
CEO Health Hub Tirol
Petra Stöckl
Gesundheitsindustrie & Life Sciences
+43 676 843 101-248
E-Mail: petra.stoeckl(at)standort-tirol.at
Human.technology Styria
Lejla Pock
CEO
Eva Bucht
PR und Marketing
+43 699 188 99 708
E-Mail: office(at)human.technology.at
International Media and Investor Relations
MC Services AG
Dr. Cora Kaiser, Dr. Johanna Kobler
+49 89 210 228 0
E-Mail: biotechaustria(at)mc-services.eu